Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) Target Price at $11.86

Posted by Brenda Bartman on Aug 31st, 2026

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) has earned an average recommendation of “Moderate Buy” from the ten research firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $12.00.

REPL has been the subject of a number of analyst reports. BMO Capital Markets raised Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective for the company in a research note on Tuesday, June 30th. Leerink Partners raised Replimune Group from a “market perform” rating to an “outperform” rating and increased their target price for the company from $11.00 to $17.00 in a research note on Tuesday, August 4th. Wolfe Research upgraded Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. Piper Sandler raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Finally, Weiss Ratings downgraded shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th.

Get Our Latest Stock Report on Replimune Group

Insider Activity

In other Replimune Group news, CFO Emily Luisa Hill sold 9,256 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $14.28, for a total value of $132,175.68. Following the sale, the chief financial officer directly owned 215,852 shares in the company, valued at approximately $3,082,366.56. This trade represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of Replimune Group stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $98,987.04. Following the transaction, the chief accounting officer directly owned 99,425 shares in the company, valued at approximately $1,289,542.25. This represents a 7.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 79,124 shares of company stock worth $1,038,364 over the last three months. Company insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AXQ Capital LP raised its holdings in Replimune Group by 4.1% during the 2nd quarter. AXQ Capital LP now owns 27,121 shares of the company’s stock worth $300,000 after buying an additional 1,056 shares during the period. ProShare Advisors LLC lifted its stake in Replimune Group by 10.3% in the fourth quarter. ProShare Advisors LLC now owns 16,116 shares of the company’s stock valued at $157,000 after buying an additional 1,505 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Replimune Group by 4.7% in the third quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock valued at $159,000 after buying an additional 1,712 shares in the last quarter. Ballentine Partners LLC boosted its holdings in shares of Replimune Group by 7.8% in the fourth quarter. Ballentine Partners LLC now owns 23,665 shares of the company’s stock valued at $230,000 after buying an additional 1,721 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after buying an additional 1,879 shares during the period. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Price Performance

Shares of REPL stock opened at $15.50 on Monday. Replimune Group has a 12 month low of $1.50 and a 12 month high of $16.15. The stock has a 50-day moving average price of $11.84 and a 200 day moving average price of $8.34. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 1.00. The firm has a market cap of $1.45 billion, a price-to-earnings ratio of -4.92 and a beta of 0.88.

Replimune Group (NASDAQ:REPL – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). Research analysts expect that Replimune Group will post -2.81 EPS for the current year.

Replimune Group Company Profile

(Get Free Report)

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.